Patent: 8,883,997
✉ Email this page to a colleague
Summary for Patent: 8,883,997
Title: | Modulation of diacylglycerol acyltransferase 2 expression |
Abstract: | Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of diseases and conditions associated with expression of diacylglycerol acyltransferase 2 are provided. |
Inventor(s): | Bhanot; Sanjay (Carlsbad, CA), Dobie; Kenneth W. (Del Mar, CA), Yu; Xing-Xian (San Diego, CA), Monia; Brett P. (Encinitas, CA) |
Assignee: | Isis Pharmaceuticals, Inc. (Carlsbad, CA) |
Application Number: | 13/566,674 |
Patent Claims: | see list of patent claims |
Details for Patent 8,883,997
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2023-08-18 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2023-08-18 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2023-08-18 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |